As shown by the data available, hyper-inflammation is considered to represent one of the most important negative prognostic factor in patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The objective of this study is to investigate new possibilities to reduce the number of patients requiring mechanical ventilation.
The aim of this study is to evaluate the benefit-risk of a single infusion of otilimab in the treatment of patients with severe COVID-19 related pulmonary disease. The study population will consist of hospitalized participants with new onset hypoxia requiring significant oxygen support or requiring early invasive mechanical ventilation.
The study will assess the efficacy and safety of MAS825 for the treatment of SARS-CoV-2 infected patients with COVID-19 pneumonia and impaired respiratory function.
This is a Phase II, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of MSTT1041A (astegolimab) or UTTR1147A in combination with standard of care (SOC) compared with matching placebo in combination with SOC in patients hospitalized with severe coronavirus disease 2019 (COVID-19) pneumonia.
The reason for this study is to see if the study drug baricitinib is effective in hospitalized participants with COVID-19.
In this study, all subjects will receive standard of care (SOC) per institutional guidelines for treatment of hospitalized patients with COVID-19 infection.
The purpose of this study is to evaluate the safety and tolerability, virologic efficacy, and clinical efficacy of REGN10933+REGN10987 compared to placebo in various instances.
The primary objective of this study is to evaluate disease progression in spontaneously breathing COVID-19 patients receiving INOpulse® treatment. This is NOT a clinical trial. Rather, it is an investigational treatment made available through the FDA's Emergency Expanded Access program.
The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration.
The primary aim of this study is to test whether Doxycycline can benefit patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections by inhibiting the replication of the virus while at the same time blocking the development of cytokine storms or inhibiting cytokine-associated coagulopathy respectively.